Xenon posts Phase 2 results for XEN1101 in major depressive disorder trial X-NOVA

Xenon Pharmaceuticals posted results this week from a completed Phase 2 trial of XEN1101 in major depressive disorder.

• XEN1101, an oral drug tested at 10 mg and 20 mg doses against placebo, was evaluated in a Phase 2, double-blind, randomized, parallel-arm, placebo-controlled trial in subjects with Major Depressive Disorder¹ known as X-NOVA (NCT05376150). The study enrolled 168 participants¹ and reached study completion on 2023-10-16. Results were first posted on 2026-09-21. The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to end of treatment at Week 6¹.